ClinicalTrials.gov
public full text
Public Domain
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy. The main questions it aims to answer are: * Is SNK02 safety and tolerable when administered weekly as an intravenous infusion * What is the maximum dose that is tolerated of SNK02 Participants will be administered SNK02 weekly for 8 weeks and undergo medical evaluation to provide initial clinical safety data for the treatment of cancer with allogeneic NK cells as a monotherapy treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib#969871
- Sorafenib Plus S-1 in Advanced Solid Tumors#847014
- A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors#981443
- Autologous Natural Killer Cells in Subjects With Plaque Psoriasis#1111706
- S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)#1124669
Record · ID 827379
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive